- Nektar Therapeutics (NKTR, Financial) announces successful Phase 2b trial results for rezpegaldesleukin in treating moderate-to-severe atopic dermatitis.
- The study met its primary endpoint with statistically significant improvements in EASI scores across all dosing arms compared to placebo (p<0.001).
- The drug demonstrated a favorable safety profile with 69.7% of patients experiencing mild-to-moderate injection site reactions as the most common side effect.
Nektar Therapeutics (NKTR) has reported promising outcomes from its Phase 2b REZOLVE-AD study, focusing on the efficacy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The study encompassed 393 patients and achieved its primary endpoint with statistically significant improvements in Eczema Area and Severity Index (EASI) scores across all dosing arms compared to placebo (p<0.001).
Key secondary endpoints were also met, with notable results including a 42% EASI-75 response in the high-dose group and significant improvements in related measures such as itch relief. The overall safety profile was encouraging, with injection site reactions being the most frequent adverse event, occurring mainly at mild-to-moderate levels.
Nektar plans to proceed with a long-term maintenance study through Q1 2026 and expects to release additional Phase 2b data concerning alopecia areata by Q4 2025. This development positions rezpegaldesleukin as a potential first-in-class treatment, offering a novel mechanism targeting regulatory T cells, which could differentiate it from existing therapies in the atopic dermatitis market.
